Both NVIDIA (NASDAQ:NVDA) and AstraZeneca (NYSE:AZN) have gained over 10% in price in the past week. NVIDIA was up due to a positive earnings beat with growth in artificial intellegence. AstraZeneca saw progress on the drug Imfinzi which is set to battle lung cancer, among other potential growth in drug pipeline research. Investors should be excited as both companies continue to execute going forward.
Parents looking to plan for their childrens college costs may need to go back to school themselves to choose among the potential options for saving money. From 529 plans to Roth IRAs to Coverdells and life insurance, there are numerous ways to save for school costsand each savings vehicle has its own ins and outs.
Did you know, for example, that the much-heralded 529 plans come in two different....More>>>
Financial and industrial stocks are leading the way in todays market rally, with the Dow and other major equity indexes hitting new highs.
The Dow Jones Industrial Average rose almost 139 points, or 0.7%, to 20,404. The S&P 500 advanced 12 points to 2,328, a rise of 0.5%. The Nasdaq Composite Index climbed more than 30 points, or 0.53%, to almost 5,764.5.
A few days ago, an article about Nike (NYSE:NKE) argued that “Nike’s shares aren’t priced to buy.” The reasoning was that “Nike is, at best, fairly valued. And it certainly isn’t trading hands at fire-sale prices.” The question is: should you expect (and wait for) fire-sales prices? Most value investors know the maxim that it is better to buy a great business....More>>>
I believe the European financial market contains too much risk, and one should rather invest in the American financial system because it has a lot more upward potential. I wrote that in one of my latest articles. However, there is one exception to my statement: UBS Group (NYSE:UBS). The Swiss banking group is especially strong in investment banking and asset management and will probably outperform....More>>>
A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.
In the world of investing, many ideas are so widely accepted that they go unquestioned. But conventional thinking is often wrong. Here's one piece of conventional investing wisdom we often hear: In times of panic, gold is a safe haven. Gold in your portfolio can help insure against losses when the stock market falls. As it turns out, this piece of conventional wisdom is correct.....More>>>
Wells Fargo’s David Maris and team call Valeant Pharmaceutical International’s (VRX) earnings and guidance “worse than feared” and contend that the struggling specialty pharmaceutical company’s “debt problem [is] coming into focus.” They explain:
Our preliminary look at 1Q results leads us to believe that Valeant is performing....More>>>
Heres how many Americans plan to spend their retirement: working.
About a third of 45- to 65-year-olds say theyll work part-time in their golden years and 4% aim to have a full-time job, changing the very meaning of retirement, according to an Ipsos/USA TODAYsurvey of 1,152 adults in mid-March.
That, of course, is once they get there. A third of those surveyed plan to delay retirement....More>>>
Singapore's largest property developer, CapitaLand (OTCPK:CLLDY) (CATL.SI) had a pretty good 2017. Helped by improving conditions in Singapore and China, not to mention significant project openings, CapitaLand's local shares climbed 20% and the ADRs did even better.
A power outage hit the CES consumer electronics show in Las Vegas, dimming the lights in one of the main convention halls hosting demonstrations from the likes of LG Electronics Inc. and Samsung Electronics Co.
“There is an isolated power outage at the Las Vegas Convention Center. W
In Lahore and Karachi, American flags were burned in front of TV cameras after President Trump’s decision on Jan. 4 to withhold $2 billion of security aid from Pakistan to punish it for allegedly harboring terrorists. The country’s government issued angry statements claiming no ins